Fractalkine promotes platelet activation and vascular dysfunction in congestive heart failure
Fractalkine promotes platelet activation and vascular dysfunction in congestive heart failure
复制标题
DOI：
10.1160/th13-08-0640
复制
发表时间：
2014-04-01
影响因子：
6.7
通讯作者：
Schaefer, Andreas
中科院分区：
文献类型：
--
作者：
Hildemann, Steven K.;Schulz, Christian;Schaefer, Andreas
充血性心力衰竭（CHF）患者内皮功能障碍和血小板反应性增强导致预后不良。CHF患者对氯吡格雷的反应性受损。Fractalkine激活血小板，并且该趋化因子的血浆水平升高是CHF的特征。我们在此探讨了在CHF患者和大鼠中fractalkine、血小板反应性和氯吡格雷疗效之间的相互关系。通过ELISA测定的CHF患者血清Fractalkine水平升高（CHF：1548 +/- 650 pg/ml;对照：968 +/- 575 pg/ml，p
Endothelial dysfunction and enhanced platelet reactivity in congestive heart failure (CHF) contribute to poor prognosis. CHF patients display an impaired responsiveness to clopidogrel. Fractalkine activates platelets and elevated plasma levels of this chemokine are a feature of CHF. We here addressed the interrelation of fractalkine, platelet reactivity and clopidogrel efficacy in humans and rats with CHF. Fractalkine serum levels determined by ELISA were increased in CHF patients (CHF: 1548 +/- 650 pg/ml; Control: 968 +/- 575 pg/ml, p